Physiopathological approach to infective endocarditis in chronic hemodialysis patients: left heart versus right heart involvement

Yassamine Bentata
Department of Nephrology, Medical School, University Mohammed the First, Oujda, Morocco

ABSTRACT
Infectious endocarditis (IE), a complication that is both cardiac and infectious, occurs frequently and is associated with a heavy burden of morbidity and mortality in chronic hemodialysis patients (CHD). About 2–6% of chronic hemodialysis patients develop IE and the incidence is 50–60 times higher among CHD patients than in the general population. The left heart is the most frequent location of IE in CHD and the different published series report a prevalence of left valve involvement varying from 80% to 100%. Valvular and perivalvular abnormalities, alteration of the immune system, and bacteremia associated with repeated manipulation of the vascular access, particularly central venous catheters, comprise the main factors explaining the left heart IE in CHD patients. While left-sided IE develops in altered valves in a high-pressure system, right-sided IE on the contrary, generally develops in healthy valves in a low-pressure system. Right-sided IE is rare, with its incidence varying from 0% to 26% depending on the study, and the tricuspid valve is the main location. Might the massive influx of pathogenic and virulent germs via the central venous catheter to the right heart, with the tricuspid being the first contact valve, have a role in the physiopathology of IE in CHD, thus facilitating bacterial adhesion? While the physiopathology of left-sided IE entails multiple and convincing mechanisms, it is not the case for right-sided IE, for which the physiopathological mechanism is only partially understood and remains shrouded in mystery.

Introduction
Brescia M. J. described the first case of infective endocarditis in a chronic hemodialysis patient in 1966, although dialysis had started a few years earlier. In this case, IE occurred in a patient who was 28 years old, had 10 months of duration of dialysis and a native arteriovenous fistula. IE was diagnosed with rheumatic aortitis and mitral valvulitis and the patient died.

For several decades, it has been well established that cardiovascular diseases and infections are the two main causes of mortality in chronic hemodialysis (CHD). Up to 40–50% of patients with end-stage renal disease (ESRD) die of cardiovascular disease (CVD) and the mortality rate due to CVD in patients on hemodialysis is 10–30 times higher than that in the general population. Infective endocarditis (IE), a complication that is both cardiac and infectious, occurs frequently and is associated with a heavy burden of morbidity and mortality in CHD. Patients receiving long-term hemodialysis (HD) are at increased risk for IE with an age-adjusted incidence ratio of 17.9 compared with the general population. About 2–6% of chronic hemodialysis patients develop IE and the incidence is 50–60 times higher among CHD patients than in the general population. Despite improvements in the prognosis of IE in the general population, the mortality rate is still much higher in hemodialysis populations due to a combination of factors, including extensive co-morbidities and virulence of germs; the mortality rate reported in different series published is 25–77%.

The patients’ immunodeficiency, repeated manipulation of the vascular access, type of vascular access used, and pre-existing valvular changes combine to place CHD patients at high risk for IE. On first thought, one might expect IE in CHD to occur in the right heart because of the frequent manipulation of the central venous catheter, similar to what occurs in intravenous drug use by drug addicts. In reality, however, the IE in CHD affects the left heart in more than 90% of cases.
Despite the high frequency and severity of IE in CHD, few series have been published in the literature over the last 30 years. Does IE remain under diagnosed or easily diagnosed in this context? Does it not raise enough interest among practitioners? Understanding of the pathophysiology of IE in HDC is not complete and several points remain unclear and unanswered. In addition, none of the published series distinguishes among the clinical, biological, and bacteriological characteristics of left heart IE and those of right heart IE, thus treating them as if they were part of the same physiopathological entity. However, we think that there are indeed two distinct entities and as in the general population, these two entities are distinct in all physiopathological, therapeutic and prognostic terms. Consequently, this physiopathological approach to IE in CHD will be presented according to the site of cardiac involvement by differentiating between left-sided IE and right-sided IE, since these two forms of IE arise from different physiopathological mechanisms. Throughout this review, we shall present, understand, and discuss the pathophysiological mechanisms involved and the distinctive elements between IE of the left heart and the IE of the right heart.

**Left-sided infective endocarditis (LSIE) in chronic hemodialysis**

**Epidemiology**

The left heart is the most frequent location of IE in CHD, and the different published series report a prevalence of left valve involvement varying from 80% to 100%. The mitral valve is the main site of IE in CHD and approximately 50% of LSIE affects the mitral valve followed by involvement of the aortic valve, while the concomitant involvement of the mitral and aortic valves has been found in 10–25% of cases. Table 1 shows the valvular sites of IE in CHD as reported by the main studies published over the past 50 years that include more than five cases. The most important series published in the literature that specified the location of endocarditis is that of Kalakannan who reported a series of 69 cases of IE in patients on chronic hemodialysis.

**Pathogenesis**

The rarity of endocarditis, despite the frequency of transient bacteremia, indicates that the intact valvular endothelium is resistant to colonization by microorganisms. Lesion development in the valvular endothelium thus seems to be an essential factor in development of IE. We shall present the different factors that cause damage to the valvular endothelium and foster bacterial growth in CHD.

Susceptibility to endocarditis in patients undergoing hemodialysis is multifactorial, with several factors playing an important role in the predisposition and the development of IE. Some of these factors are related to the quality of heart valves and others to the nature of the vascular access for hemodialysis and the state of fragility of the patient.

IE occurs in more than 90% of cases in a native valve, a valve that although certainly native, is the site of many alterations, and a degenerative process, which are both hemodynamic and lesion. Valvular calcifications play an essential role in the pathogenesis of LSIE, representing one of the most important parameters of chronic kidney disease. Mitral annular calcification (MAC) and aortic valve calcification (AVC) are the main valvular calcifications observed in ESRD. In patients undergoing long-term HD therapy, valve calcification is markedly more common, with reported prevalence rates of 50–80%, which are strongly associated with mortality. In some studies, the prevalence is even higher; Kraus reported a prevalence of mild/moderate mitral valve and aortic valve calcification in 275 patients with ESRD on hemodialysis of 98.8% and 94.4%, respectively.

These valvular and perivalvular abnormalities are closely linked to alterations of phosphocalcic metabolism, atherosclerosis, and inflammation. In fact, chronic kidney disease before the onset of ESRD leads to major phosphocalcic disturbances such as hypocalcemia, hyperphosphatemia, elevated calcium-phosphorous product, elevated parathormone, and elevated Fibroblast growth factor 23. All these abnormalities are related largely to reabsorption failure, renal excretion of calcium and phosphorous, and a faulty renal production of calcitriol. Recently, valvular calcification has also been associated with abnormalities of various calcium regulatory factors such as the level of Fetuin-A. Fetuin-A is a serum protein that stabilizes calcium–phosphate in a complex, which enables its clearing by the phagocytic system and its values decreased in patients with ESRD.

Cardiac valve calcification, frequently seen in patients undergoing dialysis, has also been regarded as a marker of atherosclerosis because the calcification process is generally similar to the process leading to atherosclerotic plaque calcification and it is characterized by the presence of monocytes, macrophages, and osteoblast-like cells. Recent studies also suggest an important role for inflammation and malnutrition in the development of valvular calcifications. Other factors contribute to the development of these valvular and
Table 1. Main characteristics and location of IE in chronic hemodialysis patients based on the presence of valvular vegetations detected by transthoracic echocardiography and/or transesophageal echocardiogram.

| Series                        | Period of study (years) | Number of cases (N) | Mean age, years | Gender, male (%) | Diabetes (%) | IDU (%) | Duration of dialysis, months | Cardiac valvular disease (%) | Mitral valve (%) | Aortic valve (%) | Mitral and aortic valves (%) | Tricuspid valve (%) | MSSA | MRSA | SE (%) | No native vascular access (%) | Overall IH mortality or at 30 d (%) |
|-------------------------------|-------------------------|---------------------|-----------------|------------------|--------------|---------|-----------------------------|-----------------------------|-----------------|-----------------|-----------------------------|---------------------|------|-------|--------|-----------------------------|------------------------|
| Leonard et al. (USA)17        | 1966–1972               | 9                   | 55              | 67               | NR           | NR      | 28.6                        | 22.3                        | 11.1            | 33.3            | 33.3                        | 22.3                 | 55.5 | 88.8  | 77.7   | 60                          | 68.4                   |
| Doulton et al. (UK)12         | 1980–2002               | 30                  | 54.1            | 60.7             | 28.5         | NR      | 46.3                        | 43.3                        | 36.6            | 16.1            | 0                           | 63.3                 | 52.1 | 30    | 60     | 77                          | 68.4                   |
| McCarthy et al. (USA)16       | 1983–1997               | 20                  | 63              | 76.4             | 35.2         | NR      | 24                          | 90                          | 45              | 25              | 20                          | 10                  | 47   | 88.2  | 47     | 60                          | 68.4                   |
| Takahashi et al. (Portugal)23 | 1985–1989               | 19                  | –               | –                | NR           | NR      | 19.5                        | NR                          | 42.1            | 31.5            | –                           | –                   | 75   | 60    | 68.4   | 60                          | 68.4                   |
| Chang et al. (Taiwan)19       | 1988–2002               | 20                  | 64              | 65               | 45           | NR      | 13                          | NR                          | 55              | 15              | 10                          | 20                  | 60   | 75    | 60     | 60                          | 68.4                   |
| Hanslik et al. (France)13     | 1988–1994               | 30                  | 62              | NR               | NR           | NR      | 43                          | 40                          | 17              | 0               | 53                          | NR                  | 43   | 37.9  | 37.9   | 37.9                        | 37.9                   |
| Robinson et al. (USA)19       | 1990–1997               | 20                  | 55              | 30               | 45           | 5       | 3.4a                        | NR                          | 50              | 15              | NR                          | 25                  | 55   | 95    | 30     | 30                          | 30                     |
| Maraj et al. (USA)69          | 1990–2000               | 32                  | 54              | 44               | NR           | 16      | 7.6a                        | NR                          | 53              | 38              | 15.3                        | 13                  | 80   | 97    | 25     | 25                          | 25                     |
| Baroudi et al. (USA)69        | 1990–2006               | 59                  | 57.3            | 47               | 59           | 7       | 52.9                        | NR                          | 63              | 17              | 13.6                        | 5.1                 | 45.7 | 91.6  | 37.9   | 37.9                        | 37.9                   |
| Kamalakannan et al. (USA)8    | 1990–2004               | 69                  | 56              | 45               | 37.7         | 11.6    | 37.10a                      | NR                          | 49.3            | 21.7            | 13                          | 10.1                | 72.3 | 88.4  | 49.3   | 49.3                        | 49.3                   |
| Tao et al. (China)24          | 1990–2009               | 6                   | 52              | 66.6             | 0            | NR      | 27a                         | 20                          | 50              | 33.4            | 16.6                        | 0                   | 33.3 | 83.4  | 33.3   | 33.3                        | 33.3                   |
| Spies et al. (Hawaii)38       | 1991–2001               | 40                  | 59              | 35               | 50           | 0       | 39.22a                      | 38                          | 52              | 23              | 20                          | 5                   | 65   | 48    | 52     | 52                          | 52                     |
| Fernandez et al. (Uruguay)11  | 1995–2000               | 21                  | 61              | 47.6             | 9.5          | 0       | 56                          | NR                          | 43              | 28.5            | 9.5                         | 19                  | 67.5 | 77    | 28.6   | 28.6                        | 28.6                   |
| Rekk et al. (Tunis)24         | 1997–2006               | 16                  | 52              | 62.5             | 6.2          | 6.2    | 27.3                        | 25                          | 56.2            | 12.5            | 6.2                         | 70.2                | 25   | 43.7  | 43.7   | 43.7                        | 43.7                   |
| Jones et al. (UK)26           | 1998–2011               | 40                  | 55              | 52.2             | 33.3         | NR      | 57.4                        | 33.3                        | 30.9            | 42.8            | NR                          | 9.5                 | 57.1 | 65    | 29.2   | 29.2                        | 29.2                   |
| Nori et al. (USA)15           | 1999–2004               | 54                  | 60              | 52               | 42           | 12      | 6a                          | NR                          | 50              | 43              | 9.2                         | 19                  | 40   | 96    | 36.5   | 36.5                        | 36.5                   |
| Oun et al. (UK)16             | 2000–2013               | 29                  | 57              | 59               | 24           | NR      | 30                          | 79.3                        | 48.3            | 17.2            | 20.7                        | 13.8                | 75.9 | 69    | 37.9   | 37.9                        | 37.9                   |
| Mangoni et al. (Italy)15      | 2004–2011               | 42                  | 66              | 69               | 42.9         | 11.9    | NR                          | NR                          | 35              | 35              | NR                          | 15                  | 67.6 | 31    | 26.2   | 26.2                        | 26.2                   |
| Kremery et al. (Slovakia)37   | 23 years                | 28                  | NR              | 36               | 0            | NR      | NR                          | NR                          | 50              | 50              | NR                          | 92.9                | 17.9 | NR    | 32.1   | 32.1                        | 32.1                   |
| Bentata et al. (Morocco)10    | 2010–2016               | 9                   | 38              | 77.7             | 33.3         | 0       | 18                          | NR                          | 22.2            | 22.2            | 0                           | 55.6                | 22.2 | 77.7  | 55.6   | 55.6                        | 55.6                   |

IDU: intravenous drug users; Cardiac valvular disease was defined by existing of valvular calcification, rheumatic disease, valve prosthesis; MSSA: methicillin-resistant Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus Aureus; SE: Staphylococcus epidermidis; no native vascular access included temporary catheter, tunneled catheter and vascular graft; NR: not reported; IH: in-hospital.

aDuration of vascular access use.
perivalvular abnormalities such as advanced age, male gender, ethnicity, duration of hemodialysis, smoking, diabetes, hypercholesterolemia, iron overload, peripheral vascular disease, cardiac dysrhythmia, and arterial hypertension.\(^{30,37–40}\)

Increased stress on the mitral and aortic valves and perivalvular structures accelerates the lesion production and degenerative processes.\(^41\) The increase of this valvular and perivalvular stress is associated with an increase in left ventricular pressure, itself secondary to systemic hypertension, cardiomyopathy, aortic stenosis, and fluid overload. All these situations are frequently observed in patients with ESRD and/or CHD contributing to the development and progression of valvular calcification.

All these valvular and perivalvular abnormalities together constitute a strong predisposing factor for IE and the valvular endothelium thus becomes sensitive to bacterial colonization, but these conditions are not sufficient to engender IE and other factors must also intervene. Alteration of the immune system and bacteremia associated with repeated manipulation of the vascular access, particularly central venous catheters in CHD patients, comprise the two main factors. Indeed, immune dysfunction in uremia is a state of both immune activation and immune suppression, an imbalance that leads to increased susceptibility to infections, as well as to inflammatory responses, which, when systemic in nature, are closely related to cardiovascular disease.\(^{42,43}\)

More than half of IE cases in CHD are preceded by an episode of bacteremia that originate in more than 70% of cases in a central venous catheter for hemodialysis. In CHD, catheter use still remains very high and international recommendations that advocate catheter use in less than 10% of patients in a hemodialysis center are difficult to achieve.\(^44\) Dialysis-related bloodstream infections account for up to 75% of deaths caused by infections among patients on HD.\(^45\)

There are four types of accesses for hemodialysis: temporary dialysis catheter, tunneled (permanent) dialysis catheter, arteriovenous fistula, and arteriovenous graft. It is established that temporary HD vascular catheters are associated with the highest rate of access-related bacteremia, followed by permanent central venous catheters, synthetic grafts, and native fistula.\(^{46–48}\) Catheter-related bacteremia (CRB) is the most common and, indeed, the most dreaded of complications. The incidence of CRB has been reported by various studies at 2.5–5.5 episodes/1000 catheter days or 0.9–2.0 episodes/person/year. This risk is two to three-fold higher for temporary HD catheters.\(^{49,50}\) There are multiple risk factors for CRB, including previous episodes of bacteremia, older age, diabetes, malnutrition, iron overload, longer duration of catheter use, and peripheral atherosclerosis.\(^51\) Repeated manipulation of the vascular access in CHD, especially when aseptic measures are not applied, is a major risk factor for CRB.\(^52\) CRB is one of the strongest parameters in the development of IE and when we reduce the frequency of CRB we can thereby drastically reduce the occurrence of IE.

It is important to note that despite the great variability between countries concerning the bacteriological epidemiology, *Staphylococcus aureus* remains the main cause of both vascular access-related bacteremia among patients receiving long-term HD and of IE, which complicates staphylococcal bacteremia in 5–10% of cases.\(^52,53\) The other germs incriminated are coagulase negative *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Klebsiella pneumonia*, and *Pseudomonas aeruginosa*.\(^54\) The appearance of methicillin-resistant *S. aureus* is continuously increasing and varies according to the series from 5% to 40%. Involvement of Candida and other species is infrequent and unusual. However, the incidence of negative blood cultures due to previous antibiotic therapy for CRB that preceded IE, or for infection at a different site remains relatively high and complicates the therapeutic management of endocarditis.

**Risk factors**

The advanced age frequently encountered in the IE of the general population is not found in the dialysis population. On the contrary, the average age is relatively young in chronic hemodialysis patients. But probably, the average age varies according to the epidemiology of the ESRD of each country and thus explains this observed difference (38 years in morocco, 52 years in Tunisia, and 63 years in United States of America).

Diabetes is one of the most frequently associated risk factors and its prevalence is higher in chronic hemodialysis patients with IE and varies from 3% to 50%.\(^8,15,17,55\) Certainly, diabetic immunodepression is added to the sphere of hemodialysis immunodepression to promote IE and aggravate the prognosis. All comorbidities and circumstances leading to immunodepression in chronic hemodialysis patients can contribute to the occurrence of endocarditis, such as viral hepatitis B and C, drug use, neoplasia, and bacteremia, even if the initial infectious point is not the central venous catheter.

Inadequate dialysis, particularly in developing countries where access to three sessions a week is sometimes difficult, can contribute to worsening patient immunity.
Right-sided infective endocarditis (RSIE) in chronic hemodialysis

Epidemiology

While the physiopathology of left-sided IE entails multiple and convincing mechanisms, it is not the case for right-sided IE, for which the physiopathologic mechanism is only partially understood and remains shrouded in mystery.

IE of the right heart represents 5–10% of IE in the general population. About 90% of RSIE occurred in subjects who were injecting drug users (IDUs) and 10% of RSIE occurred in patients with intravascular catheter for hemodialysis, implanted ports for chemotherapy, vascular prostheses, or intracardiac devices.

In the series of Jiang et al. in China, of 412 patients with IE who were candidates for surgical treatment in a period of 10 years, 35 (8.5%) had a right-sided IE, including one patient on hemodialysis, that is 2.8%. In the series of Musci et al. in Germany, in a 20-year period, 57 patients had an isolated IE of the right heart, including three on hemodialysis, that is 5.2%. In the series of Dawood et al. in the USA, in a 10-year period, 56 patients had IE (among 322 with IE) including two on CHD, that is 3.6%.

In CHD, RSIE is rare, with its incidence varying generally from 0% to 26% depending on the study, and the tricuspid valve is the main location. Some studies, however, have reported a very high incidence of more than 50%,

Pathogenesis

While LSIE develops on altered valves in a high-pressure system, RSIE on the contrary, generally develops in healthy valves that are in a low-pressure system. In CHD, the right valves are not changed and valvular and perivalvular abnormalities are absent. What then, are the physiopathological mechanisms explaining IE of the right heart in CHD? RSIE, aside from that occurring on intracardiac devices or among IDUs remains a rare and poorly understood entity. Conventional belief is that in IDUs the tricuspid valve is the first valve encountered and damaged after the intravenous injection of particulate material. In addition, endothelial damage may result from so-called jet lesions due to turbulent blood flow or may be provoked by electrodes, intracardiac devices or catheters, or by repeated intravenous injections of solid particles in IDUs.

Although these hypotheses adequately explain the pathogenesis of RSIE in IDUs, they are insufficient to explain IE in CHD because the conditions are identical to those underlying left-sided IE in CHD: inflammation, atherosclerosis, altered left valves, repeated manipulation of a hemodialysis central venous catheter, with the pathogenic germ often being a Staphylococcus. Is it related to an individual predisposition involving the expression of cytokines, the formation of immune complexes, cellular dysfunction and sensitivity to the pathogen? Might the tricuspid valve be altered in certain CHD patients? Vegetations occur more often in right-sided IE and are often large as the low pressure prevailing in the right ventricle encourages the increase in vegetation size. The prevalence of IDUs in CHD varies from 0% to 16% and the studies that reported high incidence of RSIE had a high frequency of IDUs. Nori et al. reported in their series of 54 cases of IE in CHD, 19% of RSIE and 12% of IDUs. Injectable drugs probably induce valvular endothelial lesions that favor bacterial overgrowth in staphylococcal septicemia.

Pulmonary hypertension (PHT) is another risk factor that probably plays an important role in pathogenesis of right-sided IE and its prevalence ranges from 18.8% to 68.8% in CHD. The three major causes of PHT are increased cardiac output related to hypervolemia and arteriovenous fistula, increased pulmonary vascular resistance mainly related to uremic endothelial dysfunction, pulmonary artery calcifications, and elevated pulmonary capillary wedge pressure caused by heart failure or mitral valve disease. This PHT may cause hemodynamic changes and blood flow turbulence in the right heart that lead to the vulnerability of right cardiac valves and then the occurrence of IE.

Although the microbiologic profile of RSIE does not differ from that of LSIE, S. aureus remains the major microbiological cause of RSIE in HDC patients. Might the massive influx of pathogenic and virulent germs via the central veins to the right heart with the tricuspid being the first contact valve, have a role in the physiopathology of IE in CHD, thus facilitating bacterial adhesion?

Some studies, however, do not report any case of RSIE even for large series. Aboot et al. studied risk factors of IE in a large cohort of CHD patients (n = 2075) but without specifying the site of IE. They found that a history of congestive heart failure, dysrhythmia, and decreased serum albumin at initiation of dialysis were independent factors associated with hospitalization for bacterial endocarditis. In this study, the risk for IE was constant over time after the initiation of dialysis. Table 2 summarizes the main physiopathological and risk factors that contribute to development of IE in chronic hemodialysis patients.
Table 2 The main physiopathological and risk factors of infective endocarditis in chronic hemodialysis patients.

| Physiopathological and risk factors | Factors related to underlying valvular disease | Other valvular diseases (insufficiency, stenosis, etc.) | Factors related to vascular access | Staphylococcus bacteremia related to vascular access | Long duration of hemodialysis | Advanced age | Male gender | Ethnicity (White) | Diabetes mellitus | Anemia | Atherosclerosis | Malnutrition | Iron overload | Low-serum albumin | Peripheral vascular disease | Dysrhythmia | Intravenous drug use |
|------------------------------------|-----------------------------------------------|--------------------------------------------------|-------------------------------|---------------------------------------------|--------------------------------|---------------|-------------|-----------------|-----------------|--------|----------------|-------------|--------------|------------------|----------------------|-------------|-------------------|

None of the published studies on chronic hemodialysis patients have ever separately studied the clinical, biological, and microbiological aspects of RSIE and LSIE. Consequently, it is very difficult for us to affirm the physiopathological factors in RSIE during CHD, for which the prevalence is considerably lower than for IE of the left heart.

It is important to highlight that the diagnosis of IE requires a high index of suspicion and is made using the redefined Dukes criteria combined with echocardiographic imaging, which itself fails to distinguish between RSIE and LSIE and views both as the same entity.76

Conclusion

The physiopathology of infective endocarditis remains largely unclear. The physiopathological mechanisms proposed until now do not completely explain IE and even less the reasons for which certain CHD patients develop IE of the right heart and others of the left heart, but bacteremia related to catheter infection remain the major risk factor for developing IE in CHD. What is certain is that one must not miss the diagnosis of IE and that it must be considered in any CHD patient who presents with fever, pulmonary symptomatology, anemia, or other suggestive clinical and biological signs and also during an episode of staphylococcal sepsis. Thus, patients receiving hemodialysis should be at the forefront of preventative strategies to reduce health-care associated bacteremia, and high clinical suspicion for infective endocarditis is warranted in this group.

Disclosure statement

The author reports no conflicts of interest.

References:

1. Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966;275:1089–1092.
2. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
3. Samnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–2169.
4. Abbott KC, Agodoa LY. Hospitalizations for bacterial endocarditis after initiation of chronic dialysis in the United States. Nephron 2002;91:203–209.
5. Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: Results of a 1-year survey in France. JAMA 2002;288:75–81.
6. Maraj S, Jacobs LE, Kung S-C, et al. Epidemiology and outcome of infective endocarditis in hemodialysis patients. Am J Med Sci 2002; 324:254–260.
7. Leonard A, Raij L, Shapiro FL. Bacterial endocarditis in regularly dialyzed patients. Kidney Int 1973;4:407–422.
8. Kamalakannan D, Pai RM, Johnson LB, Gardin JM, Saravolatz LD. Epidemiology and clinical outcomes of infective endocarditis in hemodialysis patients. Ann Thorac Surg 2007;83:2081–2086.
9. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993;64:95–100.
10. Haag-Weber M, Hörl WH. Uremia and infection: mechanisms of impaired cellular host defense. Nephron 1993;63:125–131.
11. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695–701.
12. Doulton T, Sabharwal N, Cairns HS, et al. Infective endocarditis in dialysis patients: new challenges and old. Kidney Int 2003;64:720–727.
13. Hanslik T, Flahault A, Vaillant JN, et al. High risk of severe endocarditis in patients on chronic dialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc 1997;12:1301–1302.
14. Rekik S, Trabelsi I, Hentati M, et al. Infective endocarditis in hemodialysis patients: Clinical features, echocardiographic data and outcome: A 10-year descriptive analysis. Clin Exp Nephrol 2009;13:350–354.
15. Nori US, Manoharan A, Thornby JI, Yee J, Parasuraman R, Ramanathan V. Mortality risk factors in chronic haemodialysis patients with infective endocarditis. *Nephrol Dial Transplant* 2006;21:2184–2190.

16. Oun HA, Price AJ, Traynor JP. Infective endocarditis in patients on haemodialysis – Possible strategies for prevention. *Scott Med J* 2016;61:97–102.

17. Krčmery V, Kisac P. Bacterial endocarditis in haemodialysis patients. Is frequent heparinisation protecting embolisation? *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* 2011;30:1627–1628.

18. Spies C, Madison JR, Schatz U. Infective endocarditis in patients with end-stage renal disease: Clinical presentation and outcome. *Arch Intern Med* 2004;164:71–75.

19. Robinson DL, Fowler VG, Sexton DJ, Corey RG, Conlon PJ. Bacterial endocarditis in hemodialysis patients. *Am J Kidney Dis Off J Natl Kidney Found* 1997;30:521–524.

20. Chang C-F, Kuo BI-T, Chen T-L, Yang W-C, Lee S-D, Lin HR. Aortic and mitral valve disease in patients with end-stage renal disease. *J Nephrol* 2006;19:221–227.

21. Fernández-Reyes MJ, Auxiliadora Bajo M, Robles P, et al. Mitral annular calcification in CAPD patients with a low degree of hyperparathyroidism. An analysis of other possible risk factors. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc* 1995;10:2090–2095.

22. Holick MF, Krane SM, Potts JT, Calcium, phosphorus and bone metabolism: Calcium regulating hormones. In: Fauci AS, ed. *Harrison’s Principles of Internal Medicine*, 14th ed. New York: Mc Graw-Hill; 1998:2214–2227.

23. Wang AY-M, Woo J, Lam CW-K, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc* 2005;20:1676–1685.

24. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. *Lancet Lond Engl* 2003;361:827–833.

25. Mohler ER, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. *Circulation* 2001;103:1522–1528.

26. Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: A hypothesis proposal. *Clin J Am Soc Nephrol CJASN* 2009;4:S49–S55.

27. Mazaferro S, Coen G, Bandini S, et al. Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc* 1993;8:335–340.

28. Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. *J Chronic Dis* 1984;37:407–415.

29. Braunwald E, Valvular heart disease. In: *Braunwald E*, ed. *Heart Disease: A Textbook of Cardiovascular Medicine*, 5th ed. Philadelphia: Saunders; 1997:1035–1048.

30. Ureña P, Malergue MC, Goldfarb B, Priëre P, Guédon-Rapoud C, Pérotrov M. Evolutive aortic stenosis and causes of immune dysfunction related to uremia and dialysis. *Perit Dial Int J Int Soc Perit Dial* 2006;28:5183–5187.

31. Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. *Am J Kidney Dis Off J Natl Kidney Found* 2006;48:S176–S247.

32. Kraus MA, Kalra PA, Hunter J, Menoyo J, Stankus N. The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: A cross-sectional observational study. *Ther Adv Chronic Dis* 2015;6:84–96.

33. Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. *J Chronic Dis* 1984;37:407–415.

34. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. *Lancet Lond Engl* 2003;361:827–833.

35. Mohler ER, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. *Circulation* 2001;103:1522–1528.

36. Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: A hypothesis proposal. *Clin J Am Soc Nephrol CJASN* 2009;4:S49–S55.

37. Mazaferro S, Coen G, Bandini S, et al. Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc* 1993;8:335–340.

38. Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. *J Chronic Dis* 1984;37:407–415.

39. Braunwald E, Valvular heart disease. In: *Braunwald E*, ed. *Heart Disease: A Textbook of Cardiovascular Medicine*, 5th ed. Philadelphia: Saunders; 1997:1035–1048.

40. Ureña P, Malergue MC, Goldfarb B, Priëre P, Guédon-Rapoud C, Pérotrov M. Evolutive aortic stenosis and causes of immune dysfunction related to uremia and dialysis. *Perit Dial Int J Int Soc Perit Dial* 2006;28:5183–5187.

41. Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. *Am J Kidney Dis Off J Natl Kidney Found* 2006;48:S176–S247.

42. Kraus MA, Kalra PA, Hunter J, Menoyo J, Stankus N. The prevalence of vascular calcification in patients with end-stage renal disease on hemodialysis: A cross-sectional observational study. *Ther Adv Chronic Dis* 2015;6:84–96.
of hemodialysis patients. Am J Infect Control 2004;32: 155–160.

46. Allon M, Daugirdas J, Depner TA, Greene T, Ornt D, Schwab SJ. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis Off J Natl Kidney Found 2006;47:469–477.

47. Lemaire X, Morena M, Leray-Moragus H, et al. Analysis of risk factors for catheter-related bacteremia in 2000 permanent dual catheters for hemodialysis. Blood Purif 2009;28:21–28.

48. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: A prospective study. Kidney Int 2000;58:2543–2545.

49. Stevenson KB, Hannah EL, Lowder CA, et al. Epidemiology of hemodialysis vascular access infections from longitudinal infection surveillance data: Predicting the impact of NKF-DOQI clinical practice guidelines for vascular access. Am J Kidney Dis Off J Natl Kidney Found 2002;39:549–555.

50. Chan MR. Hemodialysis central venous catheter dysfunction. Semin Dial 2008;21:516–521.

51. Garnacho-Montero J, Aldabó-Pallás T, Palomar-Martinez M, et al. Risk factors and prognosis of catheter-related bloodstream infection in critically ill patients: A multicenter study. Intensive Care Med 2008;34:2185–2193.

52. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis Off J Natl Kidney Found 2004;44:779–791.

53. Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunneled haemodialysis catheter bacteremia: Risk factors for bacteremia recurrence, infectious complications and mortality. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc 2006;21:1024–1031.

54. Ashby DR, Power A, Singh S, et al. Bacteremia associated with tunneled hemodialysis catheters: Outcome after attempted salvage. Clin J Am Soc Nephrol CJASN 2009;4:1601–1605.

55. Durante-Mangoni E, Pafundi PC, Ravaiso V, et al. Current features of infective endocarditis in persons on hemodialysis: A prevalence study with case control design from the prospective multicenter SEI cohort. Infection 2016;44:467–474.

56. Musci M, Sniawiaki H, Pasic M, et al. Surgical treatment of right-sided active infective endocarditis with or without involvement of the left heart: 20-year single center experience. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 2007;32:118–125.

57. Mi MY, Nelson SB, Weiner RB. Clinical and echocardiographic factors associated with in-hospital mortality in patients with infective endocarditis affecting the native tricuspid valve. Am J Cardiol 2016;118:739–743.

58. Jiang S, Li B, Zhang T, et al. Surgical treatment of isolated right-sided infective endocarditis. Tex Heart Inst J 2011;38:639–642.

59. Dawood MY, Cheema FH, Ghoreishi M, et al. Contemporary outcomes of operations for tricuspid valve infective endocarditis. Ann Thorac Surg 2015;99: 539–546.

60. Moss R, Munt B. Injection drug use and right sided endocarditis. Heart Br Card Soc 2003;89:577–581.

61. McCarthy JT, Steckelberg JM. Infective endocarditis in patients receiving long-term hemodialysis. Mayo Clin Proc 2000;75:1008–1014.

62. Bentata Y, Haddiya I, Ismaili N, et al. Infective endocarditis in chronic hemodialysis: A transition from left heart to right heart? Saudi J Kidney Dis Transpl 2016;27: 1200–1206.

63. Chambers HF, Morris DL, Täuber MG, Modin G. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med 1987;106:833–836.

64. Jain V, Yang M-H, Kovacicova-Lezcano G, Juhi LS, Bolger AF, Winston LG. Infective endocarditis in an urban medical center: Association of individual drugs with valvular involvement. J Infect 2008;57:132–138.

65. Crane LR, Levine DP, Zervos MJ, Cummings G. Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy. Rev Infect Dis 1986;8:364–373.

66. Miró JM, del Río A, Mystres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. Cardiol Clin 2003;21:167–184.

67. Sullam PM, Drake TA, Sande MA. Pathogenesis of endocarditis. Am J Med 1985;78:110–115.

68. Revilla A, López J, Villacorta E, et al. Isolated right-sided valvular endocarditis in non-intravenous drug users. Rev Esp Cardiol 2008;61:1253–1259.

69. Baroudi S, Qazi RA, Lentine KL, Bastani B. Infective endocarditis in haemodialysis patients: 16-year experience at one institution. NDT Plus 2008;1:253–256.

70. Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J Kidney Dis 2013;61:612–622.

71. Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int 2013;84:682–692.

72. Nadji G, Remadi JP, Coviaux F, et al. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditis caused by other pathogens. Heart Br Card Soc 2005;91: 932–937.

73. Takahashi C, Warrak EA, Ruzfani F. Infectious endocarditis in patients on periodic hemodialysis. AMB Rev Assoc Med Bras 1991;37:119–126.

74. Tao J-L, Ma J, Ge G-L, et al. Diagnosis and treatment of infective endocarditis in chronic hemodialysis patients. Chin Med Sci J Chung-Kuo Hsueh Tsa Chih Chin Acad Med Sci 2010; 25:135–139.

75. Ludvigsen LU, Dalgaard LS, Wiggers H, et al. Infective endocarditis in patients receiving chronic hemodialysis: A 21-year observational cohort study in Denmark. Am Heart J 2016;182:36–43.

76. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: Utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96: 200–209.